½ÃÀ庸°í¼­
»óǰÄÚµå
1279800

¼¼°èÀÇ °áÇÙ Áø´Ü ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø, Áø´Üº°, °Ë»ç À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2022-2029³â)

Global Tuberculosis Diagnostics Market Size study & Forecast, by Diagnostics Test Type, by End-User, and Regional Analysis, 2022-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°áÇÙ Áø´Ü(Tuberculosis Diagnostics)Àº °áÇÙ±Õ¿¡ ÀÇÇØ À¯¹ßµÇ´Â Àü¿°¼º °¨¿°À» Áø´ÜÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù.

ÁÖ·Î Æó¿¡ °¨¿°µÇÁö¸¸ ½ÅÀå, ôÃß, ³ú µî ½Åü ±âŸ ºÎÀ§¿¡ °¨¿°µÇ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. °áÇÙÀº °¨¿°ÀÚ ±âħ, Àçä±â, ´ëÈ­¿¡ ÀÇÇØ °ø±â·Î ÆÛÁö°íº° »ç¶÷µéÀÌ ¹ÚÅ׸®¾Æ¸¦ ÈíÀÔÇÔÀ¸·Î½á °¨¿°µË´Ï´Ù. °áÇÙ Áø´Ü ½ÃÀåÀº °áÇÙ ¹ß»ý·ü Áõ°¡, Á¤ºÎ Áö¿øÃ¥, °ü¹Î ¿¬°è °­È­ µî ¿äÀÎÀ¸·Î È®´ëµË´Ï´Ù.

½ÃÀå È®´ë¸¦ µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀº °áÇÙ°ú ´ÙÁ¦ ³»¼º °áÇÙ(MDR-TB) Áõ·Ê ¼ö°¡ Áõ°¡ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ"Global Tuberculosis Report 2021"¿¡ µû¸£¸é 2021³â 10¿ù °áÇÙȯÀÚ ´ëºÎºÐÀº µ¿³²¾Æ½Ã¾Æ(43%), ¾ÆÇÁ¸®Ä«(25%), ¼­ÅÂÆò¾ç(18%) ¹ß°ßµÆ½À´Ï´Ù. µ¿ÁöÁßÇØ(8.3%), À¯·´(2.3%) ¹ß°ßµÈ ȯÀÚ´Â Àû½À´Ï´Ù. ¶ÇÇÑ ¼¼°èº¸°Ç±â±¸(WHO)°¡ ¹ßÇ¥ÇÑ Åë°è¿¡ µû¸£¸é 2020³â ¼¼°èÀÇ ¾à 1,000¸¸¸íÀÌ °áÇÙ¿¡ °¨¿°µÇ°í, 2021³â 10¿ù¿¡´Â ¾à 150¸¸ ¸íÀÌ °áÇÙÀ¸·Î »ç¸ÁÇß½À´Ï´Ù. µû¶ó¼­ ±¹¹Îµé »çÀÌ °áÇÙ À¯º´·üÀÌ ³ô¾ÆÁü¿¡ µû¶ó º¸´Ù ¿ì¼öÇÑ Áø´Ü Åø°ú Ä¡·á¹ý ¼ö¿ä°¡ ³ô¾ÆÁö°í ¿¹Ãø ±â°£ Áß ½ÃÀå È®´ë°¡ ±â´ëµË´Ï´Ù. ¶ÇÇÑ, °í±Þ °Ë»ç ¹æ¹ý ÃâÇöÀº ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀåÀ» °¡Á®¿É´Ï´Ù. ±×·¯³ª °áÇÙ Áø´Ü ºñ¿ëÀÌ ³ô°í ±âÁ¸ °áÇÙ Áø´ÜÁ¦¿¡´Â ÇѰ谡 Àֱ⠶§¹®¿¡ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

°áÇÙ Áø´Ü ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ª, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ ¼¼°èÀÇ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â Áö¿ª °áÇ٠ȯÀÚ Áõ°¡, ÷´Ü °Ç°­ °ü¸® ½Ã½ºÅÛ ÀÌ¿ë, ³ôÀº ÀÇ·áºñ µî ¿äÀÎÀ¸·Î ÀÎÇØ ¼öÀÍ Ãø¸é ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ´ë»ó Áúȯ À¯º´·ü »ó½Â, Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, ½Å±â¼ú °³¹ß Áõ°¡ µî°ú °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®¿Í ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ¹àÈ÷°í ¾ÕÀ¸·Î ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. Á¶»ç ´ë»ó ±¹°¡ »ê¾÷ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» ÅëÇÕÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø ¿äÀΰú °úÁ¦ µî Áß¿ä Ãø¸é ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ °æÀï »óȲ°ú Áø´Ü, °Ë»ç À¯Çü, µî »ó¼¼ÇÑ ºÐ¼®°ú ´õºÒ¾î °ü°èÀÚ°¡ ÅõÀÚÇÏ´Â ¸¶ÀÌÅ©·Î ½ÃÀå ÀáÀç ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ¸¶ÄÏ ½º³À¼¦
  • ¼¼°èÀÇ, ºÎ¹®º° ½ÃÀå Ãß°è, ¿¹Ãø(2019-2029³â)
    • °áÇÙ Áø´Ü ½ÃÀå, Áö¿ªº°(2019-2029³â)
    • °áÇÙ Áø´Ü ½ÃÀå : Áø´Ü Å×½ºÆ® À¯Çüº°(2019-2029³â)
    • °áÇÙ Áø´Ü ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2019-2029³â)
  • ÁÖ¿ä µ¿Çâ
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ÀüÁ¦ Á¶°Ç

Á¦2Àå °áÇÙ Áø´ÜÁ¦ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • Á¶»ç ´ë»ó ¹üÀ§
    • »ê¾÷ ÁøÈ­
  • Á¶»ç ´ë»ó ¿¬µµ
  • ȯÀ² º¯È¯À²

Á¦3Àå °áÇÙ Áø´Ü ½ÃÀå ¿ªÇÐ

  • °áÇÙ Áø´Ü ½ÃÀå ¿µÇ⠺м®(2019-2029³â)
    • ½ÃÀå ÃËÁø ¿äÀÎ
      • °áÇÙ ÀÌȯÀ² Áõ°¡
      • Á¤ºÎ Áö¿øÀûÀÎ ´ëó
      • °ü¹Î ÆÄÆ®³Ê½Ê Áõ°¡
    • ½ÃÀå °úÁ¦
      • °áÇÙ Áø´Ü ¾à ºñ¿ëÀÌ ³ô´Ù
      • ±âÁ¸ °áÇÙÁø´ÜÁ¦ ÇѰè
    • ½ÃÀå ÁøÀÔ °¡´É¼º
      • ¼±ÁøÀûÀÎ °Ë»ç¹ý µîÀå

Á¦4Àå °áÇÙ Áø´Ü ½ÃÀå »ê¾÷ ºÐ¼®

  • Æ÷ÅÍÀÇ 5¼¼·Â ¸ðÇü
    • °ø±Þ±â¾÷ Çù»ó·Â
    • ±¸¸ÅÀÚ Çù»ó·Â
    • ½Å±Ô Âü°¡¾÷ü À§Çù
    • ´ëüǰ À§Çù
    • °æÀï ±â¾÷ °£ Àû´ë °ü°è
  • Æ÷ÅÍÀÇ 5¼¼·Â ¸ðÇü ¹Ì·¡Àû Á¢±Ù(2019-2029³â)
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
  • Åé ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ¾÷°è Àü¹®°¡º° Àü¸Á
  • ¾Ö³Î¸®½ºÆ® °á·Ð, Á¦¾ð

Á¦5Àå À§Çè Æò°¡ COVID-19 ¿µÇâ

  • COVID-19°¡ ¾÷°è¿¡ ÁÖ´Â Àüü ¿µÇâ Æò°¡
  • COVID-19 ÀÌÀü°ú COVID-19 ÀÌÈÄ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå °áÇÙ Áø´Ü ½ÃÀå : Áø´Ü¾à Å×½ºÆ® À¯Çüº°

  • ½ÃÀå ½º³À¼¦
  • °áÇÙ Áø´Ü ¾à ½ÃÀå : Áø´Ü °Ë»ç À¯Çüº°, ¼º´É-ÀáÀç ºÐ¼®
  • °áÇÙ Áø´Ü ½ÃÀå, Áø´Ü °Ë»ç À¯Çüº° ÃßÁ¤, ¿¹Ãø(2019-2029³â)
  • °áÇÙ Áø´Ü ½ÃÀå, ¼­ºê ºÎ¹®º° ºÐ¼®
    • ¿¢½º·¹ÀÌ °Ë»ç
    • ½ÇÇè½Ç °Ë»ç
    • ÇÙ»ê °Ë»ç(Nucleic Acid Testing
    • »çÀÌÅäÄ«ÀÎ °ËÃâ °Ë»ç
    • ±âŸ Áø´Ü Å×½ºÆ® À¯Çü

Á¦7Àå °áÇÙ Áø´Ü ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ½ÃÀå ½º³À¼¦
  • °áÇÙ Áø´ÜÁ¦ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°, ¼º´É-ÀáÀç ºÐ¼®
  • °áÇÙ Áø´Ü ½ÃÀå ÃÖÁ¾ »ç¿ëÀÚº° ÃßÁ¤, ¿¹Ãø(2019-2029³â)
  • °áÇÙ Áø´Ü ½ÃÀå, ¼­ºê ºÎ¹®º° ºÐ¼®
    • º´¿ø/Áø·á¼Ò
    • Áø´Ü/Á¶»ç¿¬±¸¼Ò
    • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦8Àå °áÇÙ Áø´Ü ½ÃÀå : Áö¿ªº° ºÐ¼®

  • °áÇÙ Áø´Ü ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼¦
  • ºÏ¹Ì
    • ¹Ì±¹
      • Áø´Ü °Ë»ç À¯Çüº° ÃßÁ¤, ¿¹Ãø(2019-2029³â)
      • ÃÖÁ¾ »ç¿ëÀÚº° ÃßÁ¤, ¿¹Ãø(2019-2029³â)
    • ij³ª´Ù
  • À¯·´ °áÇÙ Áø´Ü ½ÃÀå ½º³À¼¦
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ª °áÇÙ Áø´Ü ½ÃÀå ½º³À¼¦
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ª
  • ¶óƾ¾Æ¸Þ¸®Ä« °áÇÙ Áø´Ü ½ÃÀå ½º³À¼¦
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
  • ¼¼°èÀÇ ±âŸ Áö¿ª

Á¦9Àå °æÀï Á¤º¸

  • ÃÖ°í ½ÃÀå Àü·«
  • ±â¾÷ ÇÁ·ÎÇÊ
    • Abbott Laboratories
      • ÁÖ¿ä Á¤º¸
      • ÁÖ¿ä ¿ä¾à
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° ÁÖ¿ä ¿ä¾à
      • ÃÖ±Ù µ¿Çâ
    • Becton, Dickinson and Company
    • BioMerieux SA
    • Cepheid
    • F. Hoffmann-La Roche AG
    • Hain Lifescience GmbH
    • Hologic Corporation
    • Qiagen
    • AdvaCare Pharma
    • Thermo Fisher Scientific Inc.

Á¦10Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • ºñÁØ
    • ÃâÆÇ
  • Á¶»ç Ư¡
  • Á¶»ç ÀüÁ¦ Á¶°Ç
NJH 23.06.08

Global Tuberculosis (TB) Diagnostics Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029.Tuberculosis (TB) is a contagious infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also affect other parts of the body, such as the kidneys, spine, and brain. TB is spread through the air when an infected person coughs, sneezes, or talks, and others inhale the bacteria.. The Tuberculosis (TB) Diagnostics market is expanding because of factors such as increasing incidence of Tuberculosis, supportive government initiatives and increased Public-Private Partnerships.

The primary driver fueling market expansion is the increase in cases of tuberculosis and multi-drug resistant tuberculosis (MDR-TB). For instance, the World Health Organization's (WHO) Global Tuberculosis Report 2021 states that in October 2021, the majority of tuberculosis cases were discovered in South-East Asia (43%), Africa (25%), and the Western Pacific (18%), while fewer cases were discovered in the Eastern Mediterranean (8.3%), and Europe (2.3%). Additionally, according to statistics released by the World Health Organization (WHO), around 10 million individuals worldwide contracted tuberculosis in 2020, and roughly 1.5 million people died as a result of the disease in October 2021. Therefore, the increased prevalence of tuberculosis among the population drives up the demand for better diagnostic tools and therapies, which is expected to drive market expansion over the forecast period. Furthermore, advent of advanced test methods is creating lucrative growth in the market. However, high cost of tuberculosis (tb) diagnostics and limitations of existing tuberculosis (TB) diagnostics may halt market growth.

The key regions considered for the Global Tuberculosis (TB) Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to factors such as increasing number of cases of tuberculosis in the area, the availability of an advanced healthcare system, and high healthcare spending. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising prevalence of target disease, rising government initiatives, and rising development of new technology.

Major market players included in this report are:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Cepheid
  • F. Hoffmann-La Roche AG
  • Hain Lifescience GmbH
  • Hologic Corporation
  • Qiagen
  • AdvaCare Pharma
  • Thermo Fisher Scientific Inc.

Recent Developments in the Market:

  • In February 2022, SRL Diagnostics announced the launch of a whole genome sequencing test for tuberculosis The test shortens the time needed to identify multi-drug resistant tuberculosis and provides a comprehensive resistance profile to 18 different anti-TB medications.
  • Thermo Fisher Scientific Inc. introduced the SeqStudio Flex Series Genetic Analyzer, For research and development of infectious disease detection. which is anticipated to broaden the company's product line in the market.

Global Tuberculosis (TB) Diagnostics Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Diagnostic Test Type, End-User, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Diagonistics Test Typeofferings of key players. The detailed segments and sub-segment of the market are explained below.

By Diagnostic Test Type:

  • Radiographic Test
  • Laboratory Test
  • Nucleic Acid Testing
  • Cytokine Detection Test
  • Other Diagnostic Test Types

By End-User:

  • Human Tuberculosis (TB) Diagnostics
  • Tuberculosis (TB) Diagnostics Analog

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Tuberculosis (TB) Diagnostics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Tuberculosis (TB) Diagnostics Market, by Diagnostic Test Type, 2019-2029 (USD Billion)
    • 1.2.3. Tuberculosis (TB) Diagnostics Market, by End-User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Tuberculosis (TB) Diagnostics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Tuberculosis (TB) Diagnostics Market Dynamics

  • 3.1. Tuberculosis (TB) Diagnostics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of Tuberculosis
      • 3.1.1.2. Supportive government initiatives
      • 3.1.1.3. Increased Public-Private Partnerships
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Tuberculosis (TB) Diagnostics
      • 3.1.2.2. Limitations of Existing Tuberculosis (TB) Diagnostics
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advent of advanced test methods

Chapter 4. Global Tuberculosis (TB) Diagnostics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Tuberculosis (TB) Diagnostics Market, by Diagnostics Test Type

  • 6.1. Market Snapshot
  • 6.2. Global Tuberculosis (TB) Diagnostics Market by Diagnostic Test Type, Performance - Potential Analysis
  • 6.3. Global Tuberculosis (TB) Diagnostics Market Estimates & Forecasts by Diagnostic Test Type 2019-2029 (USD Billion)
  • 6.4. Tuberculosis (TB) Diagnostics Market, Sub Segment Analysis
    • 6.4.1. Radiographic Test
    • 6.4.2. Laboratory Test
    • 6.4.3. Nucleic Acid Testing
    • 6.4.4. Cytokine Detection Test
    • 6.4.5. Other Diagnostic Test Types

Chapter 7. Global Tuberculosis (TB) Diagnostics Market, by End-User

  • 7.1. Market Snapshot
  • 7.2. Global Tuberculosis (TB) Diagnostics Market by End-User, Performance - Potential Analysis
  • 7.3. Global Tuberculosis (TB) Diagnostics Market Estimates & Forecasts by End-User 2019-2029 (USD Billion)
  • 7.4. Tuberculosis (TB) Diagnostics Market, Sub Segment Analysis
    • 7.4.1. Hospitals/Clinics
    • 7.4.2. Diagnostics/Research Laboratory
    • 7.4.3. Other End-Users

Chapter 8. Global Tuberculosis (TB) Diagnostics Market, Regional Analysis

  • 8.1. Tuberculosis (TB) Diagnostics Market, Regional Market Snapshot
  • 8.2. North America Tuberculosis (TB) Diagnostics Market
    • 8.2.1. U.S. Tuberculosis (TB) Diagnostics Market
      • 8.2.1.1. Diagnostic Test Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. End-User breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Tuberculosis (TB) Diagnostics Market
  • 8.3. Europe Tuberculosis (TB) Diagnostics Market Snapshot
    • 8.3.1. U.K. Tuberculosis (TB) Diagnostics Market
    • 8.3.2. Germany Tuberculosis (TB) Diagnostics Market
    • 8.3.3. France Tuberculosis (TB) Diagnostics Market
    • 8.3.4. Spain Tuberculosis (TB) Diagnostics Market
    • 8.3.5. Italy Tuberculosis (TB) Diagnostics Market
    • 8.3.6. Rest of Europe Tuberculosis (TB) Diagnostics Market
  • 8.4. Asia-Pacific Tuberculosis (TB) Diagnostics Market Snapshot
    • 8.4.1. China Tuberculosis (TB) Diagnostics Market
    • 8.4.2. India Tuberculosis (TB) Diagnostics Market
    • 8.4.3. Japan Tuberculosis (TB) Diagnostics Market
    • 8.4.4. Australia Tuberculosis (TB) Diagnostics Market
    • 8.4.5. South Korea Tuberculosis (TB) Diagnostics Market
    • 8.4.6. Rest of Asia Pacific Tuberculosis (TB) Diagnostics Market
  • 8.5. Latin America Tuberculosis (TB) Diagnostics Market Snapshot
    • 8.5.1. Brazil Tuberculosis (TB) Diagnostics Market
    • 8.5.2. Mexico Tuberculosis (TB) Diagnostics Market
    • 8.5.3. Rest of Latin America Tuberculosis (TB) Diagnostics Market
  • 8.6. Rest of The World Tuberculosis (TB) Diagnostics Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Abbott Laboratories
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Becton, Dickinson and Company
    • 9.2.3. BioMerieux SA
    • 9.2.4. Cepheid
    • 9.2.5. F. Hoffmann-La Roche AG
    • 9.2.6. Hain Lifescience GmbH
    • 9.2.7. Hologic Corporation
    • 9.2.8. Qiagen
    • 9.2.9. AdvaCare Pharma
    • 9.2.10. Thermo Fisher Scientific Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦